The role of stromal cancer-associated fibroblasts in pancreatic cancer

Dagny Von Ahrens, Tushar D. Bhagat, Deepak Nagrath, Anirban Maitra, Amit Verma

Research output: Contribution to journalReview article

77 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refractory to conventional treatments. Cancer-associated fibroblasts (CAFs) are cellular components of the desmoplastic stroma characteristic to the tumor that contributes to this treatment resistance. Various markers for CAFs have been explored including palladin and CD146 that have prognostic and functional roles in the pathobiology of PDAC. Mechanisms of CAF-tumor cell interaction have been described including exosomal transfer and paracrine signaling mediated by cytokines such as GM-CSF and IL-6. The role of downstream signaling pathways including JAK/STAT, mTOR, sonic hedge hog (SHH), and NFkB have also been shown to play an important function in PDAC-CAF cross talk. The role of autophagy and other metabolic effects on each cell type within the tumor have also been proposed to play roles in facilitating CAF secretory function and enhancing tumor growth in a low-glucose microenvironment. Targeting the stroma has gained interest with multiple preclinical and clinical trials targeting SHH, JAK2, and methods of either exploiting the secretory capability of CAFs to enhance drug delivery or inhibiting it to prevent its influence on cancer cell chemoresistance. This review summarizes the most recent progress made in understanding stromal formation; its contribution to tumor proliferation, invasion, and metastasis; its role in chemoresistance; and potential therapeutic strategies on the horizon.

Original languageEnglish (US)
Article number76
JournalJournal of Hematology and Oncology
Volume10
Issue number1
DOIs
StatePublished - Mar 28 2017

Fingerprint

Pancreatic Neoplasms
Neoplasms
Adenocarcinoma
Paracrine Communication
Autophagy
Granulocyte-Macrophage Colony-Stimulating Factor
Cancer-Associated Fibroblasts
Cell Communication
Interleukin-6
Clinical Trials
Cytokines
Neoplasm Metastasis
Glucose
Growth
Pharmaceutical Preparations

Keywords

  • Adenocarcinoma
  • Cancer-associated fibroblast
  • Pancreas
  • Stroma
  • Tumor microenvironment

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

The role of stromal cancer-associated fibroblasts in pancreatic cancer. / Von Ahrens, Dagny; Bhagat, Tushar D.; Nagrath, Deepak; Maitra, Anirban; Verma, Amit.

In: Journal of Hematology and Oncology, Vol. 10, No. 1, 76, 28.03.2017.

Research output: Contribution to journalReview article

@article{a1074aa8249045cebed3bd41943abc93,
title = "The role of stromal cancer-associated fibroblasts in pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refractory to conventional treatments. Cancer-associated fibroblasts (CAFs) are cellular components of the desmoplastic stroma characteristic to the tumor that contributes to this treatment resistance. Various markers for CAFs have been explored including palladin and CD146 that have prognostic and functional roles in the pathobiology of PDAC. Mechanisms of CAF-tumor cell interaction have been described including exosomal transfer and paracrine signaling mediated by cytokines such as GM-CSF and IL-6. The role of downstream signaling pathways including JAK/STAT, mTOR, sonic hedge hog (SHH), and NFkB have also been shown to play an important function in PDAC-CAF cross talk. The role of autophagy and other metabolic effects on each cell type within the tumor have also been proposed to play roles in facilitating CAF secretory function and enhancing tumor growth in a low-glucose microenvironment. Targeting the stroma has gained interest with multiple preclinical and clinical trials targeting SHH, JAK2, and methods of either exploiting the secretory capability of CAFs to enhance drug delivery or inhibiting it to prevent its influence on cancer cell chemoresistance. This review summarizes the most recent progress made in understanding stromal formation; its contribution to tumor proliferation, invasion, and metastasis; its role in chemoresistance; and potential therapeutic strategies on the horizon.",
keywords = "Adenocarcinoma, Cancer-associated fibroblast, Pancreas, Stroma, Tumor microenvironment",
author = "{Von Ahrens}, Dagny and Bhagat, {Tushar D.} and Deepak Nagrath and Anirban Maitra and Amit Verma",
year = "2017",
month = "3",
day = "28",
doi = "10.1186/s13045-017-0448-5",
language = "English (US)",
volume = "10",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The role of stromal cancer-associated fibroblasts in pancreatic cancer

AU - Von Ahrens, Dagny

AU - Bhagat, Tushar D.

AU - Nagrath, Deepak

AU - Maitra, Anirban

AU - Verma, Amit

PY - 2017/3/28

Y1 - 2017/3/28

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refractory to conventional treatments. Cancer-associated fibroblasts (CAFs) are cellular components of the desmoplastic stroma characteristic to the tumor that contributes to this treatment resistance. Various markers for CAFs have been explored including palladin and CD146 that have prognostic and functional roles in the pathobiology of PDAC. Mechanisms of CAF-tumor cell interaction have been described including exosomal transfer and paracrine signaling mediated by cytokines such as GM-CSF and IL-6. The role of downstream signaling pathways including JAK/STAT, mTOR, sonic hedge hog (SHH), and NFkB have also been shown to play an important function in PDAC-CAF cross talk. The role of autophagy and other metabolic effects on each cell type within the tumor have also been proposed to play roles in facilitating CAF secretory function and enhancing tumor growth in a low-glucose microenvironment. Targeting the stroma has gained interest with multiple preclinical and clinical trials targeting SHH, JAK2, and methods of either exploiting the secretory capability of CAFs to enhance drug delivery or inhibiting it to prevent its influence on cancer cell chemoresistance. This review summarizes the most recent progress made in understanding stromal formation; its contribution to tumor proliferation, invasion, and metastasis; its role in chemoresistance; and potential therapeutic strategies on the horizon.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refractory to conventional treatments. Cancer-associated fibroblasts (CAFs) are cellular components of the desmoplastic stroma characteristic to the tumor that contributes to this treatment resistance. Various markers for CAFs have been explored including palladin and CD146 that have prognostic and functional roles in the pathobiology of PDAC. Mechanisms of CAF-tumor cell interaction have been described including exosomal transfer and paracrine signaling mediated by cytokines such as GM-CSF and IL-6. The role of downstream signaling pathways including JAK/STAT, mTOR, sonic hedge hog (SHH), and NFkB have also been shown to play an important function in PDAC-CAF cross talk. The role of autophagy and other metabolic effects on each cell type within the tumor have also been proposed to play roles in facilitating CAF secretory function and enhancing tumor growth in a low-glucose microenvironment. Targeting the stroma has gained interest with multiple preclinical and clinical trials targeting SHH, JAK2, and methods of either exploiting the secretory capability of CAFs to enhance drug delivery or inhibiting it to prevent its influence on cancer cell chemoresistance. This review summarizes the most recent progress made in understanding stromal formation; its contribution to tumor proliferation, invasion, and metastasis; its role in chemoresistance; and potential therapeutic strategies on the horizon.

KW - Adenocarcinoma

KW - Cancer-associated fibroblast

KW - Pancreas

KW - Stroma

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85016253764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016253764&partnerID=8YFLogxK

U2 - 10.1186/s13045-017-0448-5

DO - 10.1186/s13045-017-0448-5

M3 - Review article

C2 - 28351381

AN - SCOPUS:85016253764

VL - 10

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 76

ER -